These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30160394)

  • 1. Antihyperglycemic medications for cardiovascular disease risk reduction.
    Goldman JD
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S273-S278. PubMed ID: 30160394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
    Thompson J; Schacht S; Rothenberg F
    Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Scheen AJ; Wallemacq C; Jandrain B; Ernest P
    Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
    Slomski A
    JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528
    [No Abstract]   [Full Text] [Related]  

  • 7. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
    Bell RM; Yellon DM
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
    [No Abstract]   [Full Text] [Related]  

  • 8. SGLT2 inhibitors for primary prevention of cardiovascular events.
    Raz I; Cernea S; Cahn A
    J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
    [No Abstract]   [Full Text] [Related]  

  • 9. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 10. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
    Rydén L; Shahim B; Mellbin L
    Clin Ther; 2016 Jun; 38(6):1279-1287. PubMed ID: 27107734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Lingvay I; Leiter LA
    Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction.
    Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
    [No Abstract]   [Full Text] [Related]  

  • 17. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 18. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
    J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
    [No Abstract]   [Full Text] [Related]  

  • 20. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
    Raschi E; Poluzzi E; Fadini GP; Marchesini G; De Ponti F
    Diabetes Obes Metab; 2018 Dec; 20(12):2711-2723. PubMed ID: 30003655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.